Medigen Biotechnology Corp., a biotech company based in Taiwan, has in-licensed key rights for a cancer drug from Oncolys BioPharma, Inc. of Japan. Medigen will pay up to $198.9 million, including milestones, for the right to develop OBP-301 for liver cancer or an alternative indication. Plus, upon completing Phase II studies, Medigen will also have the option to acquire the Asian rights, including China and Japan, to the drug for all indications. More details...